Trial Profile

A first-in-human Phase 1 study of RE-104

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RE-104 (Primary)
Indications Postnatal depression
Focus Adverse reactions; First in man

Most Recent Events

19 May 2025 According to a Reunion Neuroscience media release, results from this study will present at the ASCP Annual Meeting, taking place May 27-30, 2025 in Scottsdale, AZ.
06 Jul 2023 New trial record
01 Jun 2023 According to a Reunion Neuroscience media release, final analysis from this study presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com